FDA authorizes Quest's combined COVID-19 and flu RT-PCR test

2016 09 02 09 36 05 93 Fda Logo V2 400

The U.S. Food and Drug Administration (FDA) said it has authorized Quest Diagnostics' RC COVID-19 +Flu reverse transcription polymerase chain reaction (RT-PCR) Test, the first combined diagnostic test for COVID-19 and influenza A and B to receive that designation using patient samples collected at home.

The kit is available for prescription use with Quest's Self-Collection Kit for COVID-190 + Flu by individuals suspected to have respiratory viral infection consistent with COVID-19 when their healthcare provider deems home collection to be appropriate, according to the FDA. After collecting their sample at home, patients can ship it to a Quest laboratory for analysis.

Page 1 of 21
Next Page